Strategic niche CNS and pulmonary focused pipeline with nine drug candidates positions P2D as a potential partner for specialized drug development and co-development agreements in niche therapeutic areas.

Early-stage leverage Small team size and preclinical to proof-of-concept focus suggests opportunities for CRO, licensing, or collaboration deals to advance assets and share development risk.

Funding signal Revenue in the lower mid-range and a clear intent to partner for later-stage development indicate readiness for licensing, out-licensing, or strategic investment discussions.

Clinical differentiation Expertise in CNS disorders and neurodegenerative diseases can be highlighted to prospective pharma partners seeking differentiated mechanisms and faster clinical data generation.

Global partner fit Portfolio alignment with major therapeutic areas overlaps common big-market indications, offering avenues for collaborations with large pharma players seeking early-stage innovation in ADHD, obesity, Alzheimer’s, TBI and COPD.